Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
Yu-Jung Cha,1,* Kyoung Soo Lim,2,* Min-Kyu Park,1 Stephen Schneider,3 Brian Bray,3 Myung-Chol Kang,3 Jae-Yong Chung,1 Seo Hyun Yoon,1 Joo-Youn Cho,1 Kyung-Sang Yu11Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, South Korea; 2...
Main Authors: | Cha YJ, Lim KS, Park MK, Schneider S, Bray B, Kang MC, Chung JY, Yoon SH, Cho JY, Yu KS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-09-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/pharmacokinetics-and-tolerability-of-the-new-second-generation-nonnucl-peer-reviewed-article-DDDT |
Similar Items
-
Exploring the clinical pharmacology of the nonnucleoside reverse transcriptase inhibitors
by: Almond, Lisa
Published: (2004) -
Binding of the Nonnucleoside Reverse Transcriptase Inhibitor Efavirenz to HIV-1 Reverse Transcriptase Monomers and Dimers
by: Braz, Valerie Ann
Published: (2009) -
Binding of the Nonnucleoside Reverse Transcriptase Inhibitor Efavirenz to HIV-1 Reverse Transcriptase Monomers and Dimers
by: Braz, Valerie Ann
Published: (2010) -
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
by: Anna Figueiredo, et al.
Published: (2006-11-01) -
Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring
by: Agata Paneth, et al.
Published: (2019-04-01)